Tre recombinase is an experimental enzyme that in lab tests has removed DNA inserted by HIV from infected cells.[1] Through selective mutation, Cre recombinase which recognizes loxP sites are modified to identify HIV long terminal repeats (loxLTR) instead. As a result, instead of performing Cre-Lox recombination, the new enzyme performs recombination at HIV provirus sites.[2]
The structure of Tre in complex with loxLTR has been resolved (PDB: 5U91), allowing for analyzing the roles of individual mutations.[3]
References
- ^ Sarkar, Indrani; Hauber, Ilona; Hauber, Joachim; Buchholz, Frank (2007). "HIV-1 proviral DNA excision using an evolved recombinase". Science. 316 (5833): 1912–15. Bibcode:2007Sci...316.1912S. doi:10.1126/science.1141453. PMID 17600219. S2CID 2437602.
- ^ Hauber, Ilona; Hofmann-Sieber, Helga; Chemnitz, Jan; et al. (September 26, 2013). "Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice". PLOS Pathogens. 9 (9): e1003587. doi:10.1371/journal.ppat.1003587. PMC 3784474. PMID 24086129.
- ^ Meinke, G; Karpinski, J; Buchholz, F; Bohm, A (19 September 2017). "Crystal structure of an engineered, HIV-specific recombinase for removal of integrated proviral DNA". Nucleic Acids Research. 45 (16): 9726–9740. doi:10.1093/nar/gkx603. PMC 5766204. PMID 28934476.
External links
|
---|
Capsid inhibitors | |
---|
Entry/fusion inhibitors (Discovery and development) |
- gp41 (Enfuvirtide (ENF, T-20))◊
- CCR5 (Maraviroc (MVC)
- Vicriviroc†, Cenicriviroc†, Leronlimab†)
- CD4 (Ibalizumab (IBA), Semzuvolimab§)
- gp120 (Fostemsavir (FTR))
|
---|
Integrase inhibitors (Integrase strand transfer inhibitors (INSTI)) |
- Bictegravir (BIC)
- Cabotegravir (CAB)
- Dolutegravir (DTG)#
- Elvitegravir (EVG)
- Raltegravir (RAL)#
- BI 224436†
- MK-2048†
|
---|
Maturation inhibitors |
- Bevirimat†
- BMS-955176§
- Fipravirimat§
|
---|
Protease Inhibitors (PI) (Discovery and development) | 1st generation |
- Amprenavir (APV)‡
- Fosamprenavir (FPV)
- Indinavir (IDV)◊
- Lopinavir (LPV)
- Nelfinavir (NFV)◊
- Ritonavir (RTV)#
- Saquinavir (SQV)◊
|
---|
2nd generation |
- Atazanavir (ATV)°#
- Darunavir (DRV)°#
- Tipranavir (TPV)◊
- TMC-310911§
|
---|
|
---|
Reverse-transcriptase inhibitors (RTIs) | Nucleoside and nucleotide (NRTI) |
- Nucleoside analogues/NRTIs: Abacavir (ABC)#
- Didanosine (ddI)◊
- Emtricitabine (FTC)
- Lamivudine (3TC)#
- Stavudine (d4T)◊
- Zalcitabine (ddC)‡
- Zidovudine (AZT, ZDV)#
- Amdoxovir†
- Apricitabine†
- Censavudine†
- Elvucitabine†
- Islatravir (EFdA, ISL)§
- Racivir†
- Stampidine†
- Nucleotide analogues/NtRTIs: Tenofovir disoproxil (TDF)#
- Tenofovir alafenamide (TAF)
|
---|
Non-nucleoside (NNRTI) (Discovery and development) | 1st generation |
- Efavirenz (EFV)#
- Nevirapine (NVP)#
- Delavirdine (DLV)‡
|
---|
2nd generation |
- diarylpyrimidines
- Dapivirine (DPV)
- Etravirine (ETR)
- Rilpivirine (RPV)
- Doravirine (DOR)
- Elsulfavirine (ESV)
|
---|
|
---|
|
---|
Combined formulations |
- Abacavir/lamivudine#
- Abacavir/dolutegravir/lamivudine°
- Abacavir/lamivudine/zidovudine
- Atazanavir/cobicistat
- Bictegravir/emtricitabine/tenofovir alafenamide°
- Cabotegravir/rilpivirine
- Darunavir/cobicistat
- Darunavir/cobicistat/emtricitabine/tenofovir alafenamide°
- Dolutegravir/emtricitabine/tenofovir alafenamide
- Dolutegravir/lamivudine°
- Dolutegravir/lamivudine/tenofovir alafenamide°
- Dolutegravir/lamivudine/tenofovir disoproxil°#
- Dolutegravir/rilpivirine
- Doravirine/lamivudine/tenofovir disoproxil
- Efavirenz/emtricitabine/tenofovir disoproxil#
- Efavirenz/lamivudine/tenofovir disoproxil#
- Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
- Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
- Emtricitabine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir disoproxil
- Emtricitabine/tenofovir disoproxil#
- Lamivudine/nevirapine/stavudine
- Lamivudine/nevirapine/zidovudine
- Lamivudine/raltegravir
- Lamivudine/tenofovir disoproxil#
- Lamivudine/zidovudine#
- Lopinavir/ritonavir#
|
---|
Pharmacokinetic boosters |
- Cobicistat (c)
- Ritonavir (r)#
|
---|
Experimental agents | |
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
°DHHS recommended initial regimen options. ◊Formerly or rarely used agent. |